Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Shionogi & Co ( (JP:4507) ) is now available.
Shionogi & Co., Ltd. announced that the FDA has accepted the New Drug Application for ensitrelvir, an investigational oral antiviral for preventing COVID-19 following exposure. If approved, it would be the first oral therapy of its kind in the U.S., potentially enhancing Shionogi’s position in the infectious disease market. The application is supported by successful Phase 3 trial results, and the drug is already approved in Japan and Singapore for COVID-19 treatment.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen2919.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, known for its innovation in infectious disease treatment and prevention. The company has made significant advancements in developing novel antimicrobials and antivirals for diseases such as HIV/AIDS, influenza, and COVID-19.
Average Trading Volume: 2,263,098
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen2242.8B
Find detailed analytics on 4507 stock on TipRanks’ Stock Analysis page.